early insertion

PreclinicalSmall molecule

early insertion is one of 5 small molecule programs targeting Vogt-Koyanagi-Harada disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vogt-Koyanagi-Harada DiseaseActive, not recruiting

Vogt-Koyanagi-Harada DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Vogt-Koyanagi-Harada Disease

#DrugCompanyPhaseTrials

Kenalog

BBausch Health Americas, Inc.

Humira

1 3

Cellcept

Roche

Preclinical

1 4

early insertion

UUniversity of Sao Paulo

Preclinical

1 5

Biologic Drugs

VVibeke Backer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Growth1 trial

Effect of t of the Etonogestrel Releasing Implant on Infant Growth and Development

Completed·UUniversity of Sao Paulo·Phase 4·NCT02469454·100 enrolled

Vogt-Koyanagi-Harada disease1 trial

Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease

Unknown status·UUniversity of Sao Paulo·N/A·NCT03399175·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for early insertion. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — early insertion compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for early insertion. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Sao Paulo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Sao Paulo

early insertion

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Growth1 trial

Vogt-Koyanagi-Harada disease1 trial

References

Drug Info

Quick Facts

Related News